查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1991413

全球關節內粘稠補充療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Viscosupplementation Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年，關節內粘稠補充療法市場規模將達到 157.2 億美元，高於 2025 年的 66.2 億美元，預計從 2026 年到 2034 年的複合年成長率將達到 10.09%。

隨著骨關節炎盛行率的不斷上升，尤其是在老年人族群中，全球關節內粘稠補充療法市場正穩步成長。關節內粘稠補充療法是將透明質酸注射到關節（尤其是膝關節）中，以改善關節潤滑並減輕疼痛。當止痛藥和物理治療等傳統治療方法效果不佳時，這種治療方法被廣泛使用。人們對微創治療的日益關注以及對有效關節疼痛管理的需求，都推動了該市場的擴張。

推動這一市場成長的關鍵因素包括全球骨關節炎和關節疾病負擔的日益加重。人口老化和肥胖率上升也推動了對關節治療方案的需求。患者和醫療專業人員擴大選擇關節內粘稠補充療法作為非手術治療關節疼痛的方法。透明質酸配方的改進和注射效果持續時間的延長也有助於提高治療效果和患者滿意度。

未來幾年，關節內粘稠補充療法市場有望受益於整形外科治療的持續進步。專注於改善注射劑配方和延長治療療程的研究有望提升臨床療效。醫療保健服務的普及和對保守關節療法認知度的提高將促進該療法的應用。隨著患者尋求創傷較小的關節疼痛管理方法並維持活動能力，關節內粘稠補充療法預計仍將是重要的治療選擇。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球關節內粘稠補充療法市場：依產品分類

  • 市場分析、洞察與預測
  • 單次注射
  • 三次注射
  • 五針

第5章：全球關節內粘稠補充療法市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 整形外科診所/門診手術中心

第6章 全球關節內粘稠補充療法市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • DePuy Synthes
    • Fidia Farmaceutici SpA
    • Sanofi
    • Smith & Nephew Plc
    • Anika Therapeutics Inc
    • Seikagaku Corporation
    • Zimmer Biomet Holdings Inc
    • Ferring Pharmaceuticals BV
    • Lifecore Biomedical LLC
    • LG Life Sciences Ltd
    • F. Hoffmann-La Roche Ltd
簡介目錄
Product Code: VMR11213813

The Viscosupplementation Market size is expected to reach USD 15.72 Billion in 2034 from USD 6.62 Billion (2025) growing at a CAGR of 10.09% during 2026-2034.

The global viscosupplementation market has grown steadily as osteoarthritis becomes more prevalent, particularly among aging populations. Viscosupplementation involves injecting hyaluronic acid into joints, especially the knee, to improve lubrication and reduce pain. This treatment option is widely used when conventional therapies such as pain medication or physical therapy provide limited relief. Increasing awareness about minimally invasive treatments and the need for effective joint pain management has contributed to the expansion of this market.

The market is driven by several important factors, including the rising global burden of osteoarthritis and joint disorders. Aging demographics and increasing rates of obesity have led to greater demand for joint treatment solutions. Patients and healthcare providers are increasingly choosing viscosupplementation as a non-surgical alternative for managing joint pain. Improvements in hyaluronic acid formulations and longer-lasting injections have also enhanced treatment effectiveness and patient satisfaction.

In the coming years, the viscosupplementation market is expected to benefit from continued advancements in orthopedic therapies. Research efforts focused on improving injection formulations and extending treatment duration may enhance clinical outcomes. Expanding healthcare access and increasing awareness about joint preservation therapies will likely drive adoption. As patients seek less invasive methods to manage joint pain and maintain mobility, viscosupplementation is expected to remain an important therapeutic option.

MARKET SEGMENTATION

By Product

  • Single Injection
  • Three Injection
  • Five Injection

By End Use

  • Hospitals
  • Orthopedic Clinics/ASCs

COMPANIES PROFILED

  • DePuy Synthes, Fidia Farmaceutici SpA, Sanofi, Smith Nephew plc, Anika Therapeutics Inc, Seikagaku Corporation, Zimmer Biomet Holdings Inc, Ferring Pharmaceuticals BV, Lifecore Biomedical LLC, LG Life Sciences Ltd, F HoffmannLa Roche Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VISCOSUPPLEMENTATION MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Single Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Three Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Five Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VISCOSUPPLEMENTATION MARKET: BY END USE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End Use
  • 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Orthopedic Clinics/ASCs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VISCOSUPPLEMENTATION MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Product
    • 6.2.2 By End Use
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Product
    • 6.3.2 By End Use
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Product
    • 6.4.2 By End Use
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Product
    • 6.5.2 By End Use
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Product
    • 6.6.2 By End Use
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL VISCOSUPPLEMENTATION INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 DePuy Synthes
    • 8.2.2 Fidia Farmaceutici S.p.A
    • 8.2.3 Sanofi
    • 8.2.4 Smith & Nephew Plc
    • 8.2.5 Anika Therapeutics Inc
    • 8.2.6 Seikagaku Corporation
    • 8.2.7 Zimmer Biomet Holdings Inc
    • 8.2.8 Ferring Pharmaceuticals B.V
    • 8.2.9 Lifecore Biomedical LLC
    • 8.2.10 LG Life Sciences Ltd
    • 8.2.11 F. Hoffmann-La Roche Ltd